MedTrace Logo

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

NCT07218211 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-02

No results posted yet for this study

Summary

The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.

Conditions

  • HIV Prevention
  • HIV Pre-exposure Prophylaxis
  • HIV Prevention Program
  • HIV Prevention and Care
  • HIV Pre-exposure Prophylaxis Use

Interventions

DRUG

Lenacapavir long-acting

Culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir)

Sponsors & Collaborators

Principal Investigators

  • Tonia Poteat, PhD · Duke University Medical Center - Professor in the School of Nursing

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-13
Primary Completion
2027-01-05
Completion
2028-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07218211 on ClinicalTrials.gov